February 2008 Volume 8 Number 2
Visit Nature Reviews Cancer online to browse the journal.
Now available at http://ealerts.nature.com/cgi-bin24/DM/y/eims0Xztnp0Hja0cZl0Ee
Please note that you need to be a subscriber to enjoy full text access to Nature Reviews Cancer online.
To purchase a subscription, please visit: http://ealerts.nature.com/cgi-bin24/DM/y/eims0Xztnp0Hja0a5J0ER
Alternatively, to recommend a subscription to your library, please visit
http://ealerts.nature.com/cgi-bin24/DM/y/eims0Xztnp0Hja0sRD0E7
*********************************************************************
Nature Reviews Cancer Impact Factor: 31.583*
(*Journal Citation Reports, Thomson, 2006)
*********************************************************************
=====================================================================
IT'S NOW FREE TO POST YOUR VACANCY ON
naturejobs.com http://ealerts.nature.com/cgi-bin24/DM/y/eims0Xztnp0Hja0bZD0Ex
It's the breakthrough you've been waiting for. Naturejobs.com — the scientific jobs board from Nature —
now lets you advertise your vacancy completely FREE OF CHARGE
Go to http://ealerts.nature.com/cgi-bin24/DM/y/eims0Xztnp0Hja0BGJp0E5 or telephone:
Europe: +44 (0) 20 78434961
US: + 1 800 9897718
=====================================================================
=====================================================================
Targeting lipid signalling in disease
A Free Poster from Nature Reviews Molecular Cell Biology
This FREE poster from Nature Reviews Molecular Cell Biology provides an overview of the protein-lipid signalling network and how this network can be exploited pharmacologically
to attenuate proliferative, inflammatory and metabolic diseases.
Access this Poster online!
http://ealerts.nature.com/cgi-bin24/DM/y/eims0Xztnp0Hja0BlsB0Ec
The Poster accompanies a special Focus issue on Lipids.
Access to the Focus content is free throughout February.
http://ealerts.nature.com/cgi-bin24/DM/y/eims0Xztnp0Hja0BlsC0Ed
Poster produced with support from: Merck Serono International S.A.
=====================================================================
=====================================================================
This month's FEATURED article:
FBW7 ubiquitin ligase: a tumour suppressor at the crossroads of cell division, growth and differentiation
Markus Welcker and Bruce E. Clurman
p83 | doi:10.1038/nrc2290
http://ealerts.nature.com/cgi-bin24/DM/y/eims0Xztnp0Hja0BlsD0Ee
=====================================================================
From the editors
p73 | doi:10.1038/nrc2327
http://ealerts.nature.com/cgi-bin24/DM/y/eims0Xztnp0Hja0BlsE0Ef
----------------------
RESEARCH HIGHLIGHTS
----------------------
Cell signalling: Balancing act
p75 | doi:10.1038/nrc2320
http://ealerts.nature.com/cgi-bin24/DM/y/eims0Xztnp0Hja0BlsF0Eg
Signalling: Structural survey
p76 | doi:10.1038/nrc2315
http://ealerts.nature.com/cgi-bin24/DM/y/eims0Xztnp0Hja0BlsG0Eh
Drug resistance: Destabilizing influence
p76 | doi:10.1038/nrc2316
http://ealerts.nature.com/cgi-bin24/DM/y/eims0Xztnp0Hja0BlsH0Ei
IN THE NEWS
Within spitting distance
p76 | doi:10.1038/nrc2323
http://ealerts.nature.com/cgi-bin24/DM/y/eims0Xztnp0Hja0BlsI0Ej
TRIAL WATCH
Language function in patients with glioma
p77 | doi:10.1038/nrc2324
http://ealerts.nature.com/cgi-bin24/DM/y/eims0Xztnp0Hja0BlsJ0Ek
Cell death: ..and a nice Chianti
p78 | doi:10.1038/nrc2313
http://ealerts.nature.com/cgi-bin24/DM/y/eims0Xztnp0Hja0BlsK0El
Tumorigenesis: First or last?
p78 | doi:10.1038/nrc2314
http://ealerts.nature.com/cgi-bin24/DM/y/eims0Xztnp0Hja0BlsL0Em
IN BRIEF
Mouse models | Mouse models | Tumour suppressors | Diet
p79 | doi:10.1038/nrc2322
http://ealerts.nature.com/cgi-bin24/DM/y/eims0Xztnp0Hja0BlsM0En
Genetics: In the driving seat
p80 | doi:10.1038/nrc2318
http://ealerts.nature.com/cgi-bin24/DM/y/eims0Xztnp0Hja0BlsN0Eo
Signalling: The GEP100 pathway to invasion
p80 | doi:10.1038/nrc2319
http://ealerts.nature.com/cgi-bin24/DM/y/eims0Xztnp0Hja0BlsO0Ep
Nanotechnology: Drawing tumour cells from blood
p81 | doi:10.1038/nrc2317
http://ealerts.nature.com/cgi-bin24/DM/y/eims0Xztnp0Hja0BlsP0Eq
----------------------
REVIEWS
----------------------
FBW7 ubiquitin ligase: a tumour suppressor at the crossroads of cell division, growth and differentiation
Markus Welcker and Bruce E. Clurman
p83 | doi:10.1038/nrc2290
The tumour suppressor FBW7 is the substrate recognition component of the SCF-type ubiquitin ligase that degrades several proto-oncogenes, including MYC and cyclin E. How do the numerous cancer-associated mutations in FBW7 and its substrates contribute to tumorigenesis?
Abstract: http://ealerts.nature.com/cgi-bin24/DM/y/eims0Xztnp0Hja0BlsQ0Er
Article: http://ealerts.nature.com/cgi-bin24/DM/y/eims0Xztnp0Hja0BlsD0Ee
New approaches for imaging tumour responses to treatment
Kevin Brindle
p94 | doi:10.1038/nrc2289
Tumour responses to treatment are still largely assessed from imaging measurements of reductions in tumour size, which can take weeks to be manifest. This Review presents the new non-invasive techniques that can give early evidence of tumour response.
Abstract: http://ealerts.nature.com/cgi-bin24/DM/y/eims0Xztnp0Hja0BlsR0Es
Article: http://ealerts.nature.com/cgi-bin24/DM/y/eims0Xztnp0Hja0BlsS0Et
DNA vaccines: precision tools for activating effective immunity against cancer
Jason Rice, Christian H. Ottensmeier and Freda K. Stevenson
p108 | doi:10.1038/nrc2326
DNA vaccines against cancer allow a high degree of molecular precision, but until recently translation into the clinic has been difficult. Advances in delivery techniques are now allowing them to fulfil their potential.
Abstract: http://ealerts.nature.com/cgi-bin24/DM/y/eims0Xztnp0Hja0BlsT0Eu
Article: http://ealerts.nature.com/cgi-bin24/DM/y/eims0Xztnp0Hja0BlsU0Ev
Diagnosing and exploiting cancer's addiction to blocks in apoptosis
Anthony G. Letai
p121 | doi:10.1038/nrc2297
Cancer cells survive despite violating rules that ordinarily provoke apoptosis. Now that we understand more about how members of the BCL2 family of proteins regulate apoptosis, can we exploit our knowledge to more effectively target cancer cells?
Abstract: http://ealerts.nature.com/cgi-bin24/DM/y/eims0Xztnp0Hja0BlsV0Ew
Article: http://ealerts.nature.com/cgi-bin24/DM/y/eims0Xztnp0Hja0BlsW0Ex
Ral GTPases and cancer: linchpin support of the tumorigenic platform
Brian O. Bodemann and Michael A. White
p133 | doi:10.1038/nrc2296
The Ras-family G-proteins RALA and RALB seem to be key offenders in the subversion of core biological systems driving oncogenic transformation. This up-to-date Review focuses on current developments within this field.
Abstract: http://ealerts.nature.com/cgi-bin24/DM/y/eims0Xztnp0Hja0BlsX0Ey
Article: http://ealerts.nature.com/cgi-bin24/DM/y/eims0Xztnp0Hja0BlsY0Ez
----------------------
PERSPECTIVES
----------------------
OPINION
Is cell competition relevant to cancer?
Eduardo Moreno
p141 | doi:10.1038/nrc2252
This Perspective provides an intriguing look at cell competition, which was originally described in Drosophila melanogaster more than 30 years ago. How do cells compete with one another, and how might this process relate to cancer?
Abstract: http://ealerts.nature.com/cgi-bin24/DM/y/eims0Xztnp0Hja0BlsZ0E1
Article: http://ealerts.nature.com/cgi-bin24/DM/y/eims0Xztnp0Hja0Blsa0E8
SCIENCE AND SOCIETY
Translation of new cancer treatments from pet dogs to humans
Melissa Paoloni and Chand Khanna
p147 | doi:10.1038/nrc2273
Naturally occurring cancers in pet dogs are similar to those in humans, and there is a growing interest in using studies in dogs to complement research in humans and mice. How can the study of pet dogs contribute to the development of new cancer therapeutics?
Abstract: http://ealerts.nature.com/cgi-bin24/DM/y/eims0Xztnp0Hja0Blsb0EA
Article: http://ealerts.nature.com/cgi-bin24/DM/y/eims0Xztnp0Hja0Blsc0EB
=====================================================================
Nature Methods' Method of the Year 2007
Technological developments often drive scientific progress, so let's celebrate
methods development for its own sake! Nature Methods' editors have selected the methodological development that most impressed them in 2007 because it came into its own and started impacting a wide variety of research areas. Visit the website to discover the champion, read the story of its development and hear from expert users about its applications.
And since the decision was tough, there is also a selection of 'Methods to Watch' for the years to come!
http://ealerts.nature.com/cgi-bin24/DM/y/eims0Xztnp0Hja0BkAq0EY
=====================================================================
You have been sent this Table of Contents Alert because you have opted in to receive it. You can change or discontinue your e-mail alerts at any time, by modifying your preferences on your nature.com account at:
http://ealerts.nature.com/cgi-bin24/DM/y/eims0Xztnp0Hja0Zzu0EC
(You will need to log in to be recognised as a nature.com registrant).
For further technical assistance, please contact our registration department:
registration@nature.com
For print subscription enquiries, please contact our subscription department:
subscriptions@nature.com
For other enquiries, please contact our customer feedback department:
feedback@nature.com
Nature Publishing Group | 75 Varick Street, 9th Floor | New York | NY 10013-1917 | USA
Nature Publishing Group's worldwide offices:
London - Paris - Munich - New Delhi - Tokyo - Melbourne -
San Diego - San Francisco - Washington - New York - Boston
(c) Copyright 2008 Nature Publishing Group
=====================================================================
